Tunneled Peripherally Inserted Central Catheters Market - Global Forecast 2026-2032

The Tunneled Peripherally Inserted Central Catheters Market size was estimated at USD 2.33 billion in 2025 and expected to reach USD 2.56 billion in 2026, at a CAGR of 13.83% to reach USD 5.78 billion by 2032.

The critical role of tunneled peripherally inserted central catheters (PICCs) in supporting complex infusion therapies has become increasingly evident against the backdrop of rising incidences of sepsis and chronic disease management. In 2019, the United States recorded 201,092 sepsis-related deaths, with three-fourths of those fatalities occurring among adults aged 65 and over, underscoring the imperative for reliable central venous access to deliver timely antimicrobial treatments and fluid resuscitation.

Clinical data reveal that antibiotic therapy remains the predominant indication for PICC placement, accounting for 34.5% of insertions, followed by difficult vascular access or blood draws at 21.6%, while chemotherapy use constitutes 15.7% of cases. These patterns underscore the versatility of tunneled PICCs in addressing a spectrum of therapeutic needs, from prolonged antimicrobial regimens to parenteral nutrition and cancer care. Moreover, the integration of evidence-based appropriateness guidelines has driven a significant uptick in institutional adoption of vascular access oversight committees and decision support tools, markedly enhancing patient safety and catheter utilization practices.

Looking ahead, the evolution of tunneled PICCs reflects a convergence of clinical demand and technological innovation. As healthcare providers seek to optimize long-term infusion outcomes, the strategic importance of PICCs in outpatient oncology, home infusion therapy, and intensive care settings will continue to grow. This introduction sets the stage for a detailed examination of the transformative shifts, regulatory impacts, segmentation insights, regional dynamics, competitive landscape, actionable recommendations, and methodological foundations that shape the modern tunneled PICC market.

A wave of technological advancements and practice innovations has fundamentally reshaped the landscape of tunneled PICC deployment. The advent of integrated imaging and navigation systems exemplifies this shift. In late 2023, Becton, Dickinson and Company introduced the SiteRite™ 9 ultrasound system featuring real-time needle tracking and tip confirmation, enabling clinicians to achieve first-attempt insertion success and reduce procedural complications. This level of precision has set a new benchmark for vascular access device placement, accelerating adoption among both veteran practitioners and trainees.

Simultaneously, catheter tip navigation devices have become more sophisticated, with Teleflex’s Arrow™ VPS Rhythm™ DLX device and NaviCurve™ stylet demonstrating how electrocardiographic tip tracking and anatomically guided curves can eliminate the need for confirmatory x-rays in eligible cases. These innovations support workflow efficiency and patient comfort, reflecting a broader trend toward smart catheter systems that blend engineering with clinical insight.

Beyond procedural enhancements, materials science has introduced antimicrobial and antithrombogenic coatings that actively mitigate central line-associated bloodstream infections and thrombotic events. Research partnerships between industry leaders and infection prevention consortia are yielding advanced polymer formulations that extend catheter dwell times while maintaining biocompatibility. Taken together, these paradigm shifts in imaging guidance, navigation technology, and bioengineered materials are redefining best-in-class PICC solutions and elevating the standard of care for vascular access.

The United States’ trade policies in 2024 and 2025 have introduced significant cost variables for medical device supply chains. Section 301 tariff increases, implemented in phases beginning September 27, 2024, and January 1, 2025, imposed a 100% duty on syringes and needles, a 50% duty on rubber medical gloves, and elevated rates on respirators, masks, and related products. While these measures target specific import codes, the ripple effects extend to infusion therapy kits and ancillary consumables used in PICC insertion and maintenance, driving procurement and inventory planning challenges for healthcare providers.

Importantly, tunneled PICCs classified under HTS subheading 9018.39 remain exempt from these additional Section 301 duties, with general duty rates at 0% for U.S. imports. This exemption underscores the strategic value of PICCs within the broader portfolio of central venous access devices. Nevertheless, the increased costs of associated needles, securement products, and protective equipment have compressed margins for device manufacturers and elevated the total delivered cost for end users.

Against this backdrop, medical supply distributors and hospital purchasing consortia are revisiting contract structures to absorb or pass through tariff-induced cost increases. Several large healthcare systems have initiated multi-year sourcing agreements and domestic production partnerships to mitigate tariff risk and ensure continuity of care. As 2025 unfolds, stakeholders must maintain agility in procurement strategies, leveraging tariff exemptions and exploring alternative sourcing models to safeguard both financial performance and patient outcomes.

Insight into core segmentation categories reveals differentiated value propositions and clinical use cases for tunneled PICCs. Within application segments, the device’s adaptability across antibiotic therapy, chemotherapy, infusion therapy, and nutritional therapy underscores its versatility; providers tailor catheter configurations to optimize flow rates and minimize complications based on therapeutic demands. Lumen configurations further refine clinical outcomes, as single-lumen designs reduce infection risk in straightforward infusion protocols, while double and triple lumen options enable concurrent administration of multiple agents and blood sampling without additional venous access procedures.

Material selection plays a pivotal role in device performance and patient comfort. Polyurethane catheters offer enhanced tensile strength and low profile, supporting extended indwelling durations, whereas silicone-based options provide superior flexibility and biocompatibility for patients with heightened sensitivity or fragile veins. End user segmentation highlights the nuances of product adoption: ambulatory surgical centers, independent infusion centers, and physician office-based infusion clinics prioritize ease of insertion and streamlined workflows, while private and public hospitals allocate resources toward comprehensive vascular access teams and advanced imaging modalities. Specialty clinics, particularly oncology centers, demand kits that integrate securement and antimicrobial technologies to adhere to stringent infection-prevention protocols.

Product type distinctions between non-valved and valved catheters further enable customization of therapy regimens. Valved catheters reduce the need for external clamps and heparin locks, enhancing safety and simplifying maintenance, whereas non-valved designs remain cost-effective for high-volume infusion settings. These segmentation insights illustrate how a nuanced understanding of application context, device architecture, material properties, and care setting preferences informs both product development and go-to-market strategies in the tunneled PICC landscape.

Regional dynamics significantly influence the adoption and deployment of tunneled PICC systems. In the Americas, robust reimbursement frameworks and established home health networks have accelerated the shift toward outpatient infusion models, with integrated care pathways facilitating seamless transitions from hospital to home. Notably, Vizient’s January 2025 contract award to Teleflex for central venous access catheters and arterial catheters reflects this region’s emphasis on strategic group purchasing alliances to secure cost-effective, high-quality device portfolios.

In Europe, Middle East & Africa (EMEA), healthcare regulators and payers place intensified focus on value-based procurement and infection-prevention benchmarks. Broadly proposed tariffs on EU medical exports have prompted industry stakeholders to advocate for exemptions, warning of potential delays in critical equipment procurement and downstream impacts on patient access. Concurrently, national health systems in the UK and Germany are driving standardization of vascular access protocols, reinforcing the adoption of ultrasound-guided insertion and securement best practices to curtail central line-associated bloodstream infections.

Asia-Pacific markets demonstrate divergent trajectories, with advanced economies in Japan and Australia emphasizing regulatory convergence with global safety standards, while emerging markets in China and India leverage domestic manufacturing capabilities to support cost-sensitive patient populations. Catheters under HTS 9018.39 entering China face a 4% most-favored-nation tariff and a 17% general tariff, underscoring the interplay between cross-border trade policies and local price competitiveness. Across APAC, collaborations between manufacturers and government health agencies prioritize localized clinical training programs to expand skilled PICC placement capacity and optimize vascular access management.

The competitive landscape of tunneled PICCs is defined by strategic divestitures, technology investments, and supply chain diversification among leading players. AngioDynamics’ divestiture of its PICC and midline business to Spectrum Medical in February 2024 generated a milestone payment of $5.5 million, reflecting a strategic refocus on core interventional oncology and peripheral vascular therapies. This transaction underscores the value associated with dedicated infusion device platforms and the importance of aligning portfolio composition with growth priorities.

Becton, Dickinson and Company continues to innovate its PICC ecosystem while addressing safety concerns. In early 2025, BD received an FDA early alert regarding material fatigue leaks in PowerPICC Intravascular Catheters and recommended removal of affected product lots, reaffirming its commitment to post-market vigilance and risk mitigation. Concurrently, BD’s investment of over $30 million to expand U.S. catheter line capacity at its Utah facility exemplifies efforts to bolster domestic manufacturing resiliency and reduce exposure to tariff-related cost pressures.

Teleflex has reinforced its leadership in insertion technology, launching the Arrow™ VPS Rhythm™ DLX device with TipTracker™ navigation and the NaviCurve™ stylet to enhance first-attempt success rates and tip placement accuracy. In tandem, the organization’s contract win with Vizient for central venous access catheters underscores the strategic importance of group purchasing agreements in securing long-term market share.

ICU Medical has expanded its infusion portfolio through targeted product development and educational initiatives. The company’s Infusion Assessment Program earned the INS Seal of Approval in 2025, reflecting its leadership in competency-based training and adherence to infusion therapy standards. These collective competitive movements illustrate an industry in flux, where mergers, recalls, capacity expansions, and clinical education intersect to shape the future of tunneled PICC innovation and adoption.

Industry stakeholders must adopt a proactive approach to capitalize on emerging PICC market opportunities and mitigate operational risks. Companies should accelerate the integration of smart navigation and tip confirmation technologies into their catheter systems to differentiate their offerings and meet the growing demand for first-attempt insertion success in both inpatient and outpatient settings.

Developing resilient supply chains is critical amid evolving trade policies and tariff regimes. Strategic partnerships with domestic manufacturers and alternative sourcing agreements can shield organizations from import duty volatility while ensuring consistent product availability. Collaborative frameworks between device manufacturers and healthcare providers can also facilitate joint investment in localized warehousing and rapid replenishment models.

Enhancing stakeholder engagement through targeted training and educational initiatives will sustain best practices in PICC insertion and maintenance. Manufacturers and distributors should co-create competency-based curricula with professional societies and clinical consensus bodies to promote standardized vascular access protocols, reinforce infection prevention strategies, and drive adherence to evidence-based guidelines.

Finally, portfolio optimization through portfolio rationalization and technology licensing can align product lines with market demand. Prioritizing antimicrobial and antithrombogenic catheter variants, valved designs, and extended-dwell materials will address unmet clinical needs and support reimbursement positioning under value-based care frameworks. By executing these strategic imperatives, industry leaders can navigate complex market dynamics and deliver superior clinical and economic outcomes.

This study is grounded in a comprehensive multi-stage research methodology designed to ensure the rigor and credibility of its findings. The initial phase entailed secondary research, encompassing an exhaustive review of regulatory filings, FDA safety communications, tariff notifications, and peer-reviewed clinical literature to establish foundational insights into device classifications, clinical applications, and trade policies.

Primary research was conducted through structured interviews with key opinion leaders, including vascular access specialists, infusion nurses, and procurement executives, to validate secondary data and gather nuanced perspectives on evolving product preferences, procedural workflows, and region-specific adoption drivers. These engagements were complemented by an online survey of procurement and clinical stakeholders to quantify adoption barriers and technology requirements across care settings.

Data triangulation techniques were employed to reconcile quantitative inputs-such as tariff rates, procurement tenders, and company financial disclosures-with qualitative insights from expert dialogues. The synthesis of these inputs allowed for robust segmentation analysis and identification of strategic themes. Finally, draft findings underwent peer review by a council of clinical advisors and industry analysts to ensure accuracy, relevance, and applicability to decision-makers.

The analysis presented in this executive summary delineates a dynamic and evolving PICC market landscape marked by technological breakthroughs, regulatory influences, and strategic industry realignments. Innovations in imaging guidance and catheter bioengineering have elevated procedural efficacy and patient safety, while Section 301 tariff adjustments have underscored the importance of supply chain resilience and strategic sourcing.

Segmentation insights illustrate how application context, lumen configurations, material composition, and care setting preferences intersect to inform product development and commercialization strategies. Regional examinations highlight differentiated growth drivers, from outpatient infusion expansion in the Americas to value-based procurement in EMEA and manufacturing-led competitiveness in Asia-Pacific.

Leading companies are responding with targeted divestitures, capacity enhancements, smart navigation systems, and clinical education programs to fortify their competitive positions. To thrive, stakeholders must implement actionable strategies that harness smart device integration, diversify sourcing pathways, engage clinical end users through training partnerships, and optimize product portfolios under value-based care models.

As the tunneled PICC sector continues to mature, a steadfast commitment to innovation, collaboration, and evidence-based practice will be essential for delivering superior clinical outcomes and sustaining market leadership.

To explore how you can leverage this comprehensive analysis for strategic decision-making and drive growth in the tunneled PICC segment, connect with Ketan Rohom, Associate Director of Sales & Marketing. His deep expertise in vascular access devices and market dynamics ensures you receive tailored guidance on product positioning, competitive strategy, and customer engagement. By partnering with Ketan, you gain access to exclusive insights, proprietary data, and expert recommendations that empower you to navigate complex market forces and accelerate adoption of tunneled PICC technologies across key clinical settings. Reach out today to secure your copy of this market research report and transform your strategic outlook on tunneled peripherally inserted central catheters.